MCID: GST030
MIFTS: 45

Gastrinoma

Categories: Cancer diseases, Gastrointestinal diseases, Neuronal diseases

Aliases & Classifications for Gastrinoma

MalaCards integrated aliases for Gastrinoma:

Name: Gastrinoma 12 54 44 15 70
Gastrin Secreting Tumor 12
Gastrinoma, Malignant 70
Malignant Gastrinoma 12
Gastrin Cell Tumour 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5577
MeSH 44 D015408
NCIt 50 C3050
SNOMED-CT 67 16189002
UMLS 70 C0017150 C0334283

Summaries for Gastrinoma

Disease Ontology : 12 A neuroendocrine tumor that results in an overproduction of gastric acid.

MalaCards based summary : Gastrinoma, also known as gastrin secreting tumor, is related to zollinger-ellison syndrome and duodenal gastrinoma. An important gene associated with Gastrinoma is MEN1 (Menin 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Dexlansoprazole and Lansoprazole have been mentioned in the context of this disorder. Affiliated tissues include pancreas, lymph node and liver, and related phenotypes are behavior/neurological and endocrine/exocrine gland

Wikipedia : 73 Gastrinomas are neuroendocrine tumors (NETs), usually located in the duodenum or pancreas, that secrete... more...

Related Diseases for Gastrinoma

Diseases related to Gastrinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 220)
# Related Disease Score Top Affiliating Genes
1 zollinger-ellison syndrome 32.1 SST SCT MEN1 GRP GAST CHGA
2 duodenal gastrinoma 32.0 SST SCT MEN1 GAST CHGA
3 pancreatic gastrinoma 32.0 SST SCT MEN1 GAST CHGA
4 gastric gastrinoma 31.9 SCT MEN1 GAST CHGA
5 multiple endocrine neoplasia 31.1 VIP SST SCT POMC MEN1 GAST
6 diarrhea 30.7 SST SCT POMC GAST
7 peptic ulcer disease 30.7 SST SCT MEN1 GRP GAST
8 atrophic gastritis 30.5 SST MEN1 GAST CHGA
9 duodenal ulcer 30.4 SST SCT INS GRP GAST
10 carcinoid syndrome 30.4 SST MEN1 CHGA
11 hyperparathyroidism 30.4 SCT MEN1 GAST CHGA CASR
12 glucagonoma 30.3 VIP SST SCT GAST CHGA
13 parathyroid adenoma 30.2 MEN1 CHGA CASR
14 hyperinsulinemic hypoglycemia 30.2 SST MEN1 INS
15 autoimmune atrophic gastritis 30.2 GAST CHGA
16 duodenitis 30.2 INS GAST
17 mixed ductal-endocrine carcinoma 30.2 GAST CHGA
18 conn's syndrome 30.2 SST POMC MEN1 CHGA
19 neuroendocrine carcinoma 30.1 SST MEN1 GRP GAST CHGA
20 gastritis 30.1 SST SCT GAST CHGA CCKBR
21 hypokalemia 30.1 POMC INS CASR
22 ectopic cushing syndrome 30.1 SST POMC CHGA
23 gastric neuroendocrine neoplasm 30.1 SST MEN1 GAST CHGA
24 secretory diarrhea 29.9 VIP SST GRP
25 cholelithiasis 29.9 SST INS GAST
26 pituitary tumors 29.8 SSTR5 SST POMC MEN1
27 pernicious anemia 29.8 SST SCT GAST CHGA
28 multiple endocrine neoplasia, type i 29.8 VIP SST SCT POMC MEN1 INS
29 primary hyperparathyroidism 29.8 POMC MEN1 INS GAST CHGA CASR
30 nephrolithiasis 29.8 MEN1 INS CASR
31 hyperthyroidism 29.7 SST POMC INS
32 tuberous sclerosis 29.5 SST POMC INS CHGA
33 hyperprolactinemia 29.5 VIP SST POMC INS
34 carcinoid tumors, intestinal 29.5 SSTR2 SST MEN1 GAST CHGA
35 insulinoma 29.5 SSTR5 SSTR2 SST SCT MEN1 INS
36 islet cell tumor 29.4 VIP SST SCT MEN1 INS GAST
37 vipoma 29.4 VIP SST SCT MEN1 GAST CHGA
38 neuroendocrine tumor 29.1 VIP SSTR2 SST SCT POMC MEN1
39 pituitary adenoma, prolactin-secreting 28.9 SSTR5 SSTR2 SSTR1 SST POMC MEN1
40 somatostatinoma 28.9 VIP SSTR2 SST MEN1 INS GAST
41 adenoma 28.9 SSTR5 SSTR2 SST POMC MEN1 CHGA
42 pancreatic endocrine carcinoma 28.8 SSTR5 SSTR2 SST MEN1 INS GAST
43 pheochromocytoma 28.8 VIP SSTR1 SST POMC MEN1 GRP
44 hyperpituitarism 28.4 SSTR5 SSTR2 SSTR1 SST POMC MEN1
45 acromegaly 28.4 VIP SSTR5 SSTR2 SSTR1 SST POMC
46 pancreatic cancer 27.3 VIP SSTR2 SST SCTR SCT MEN1
47 goblet cell carcinoid 10.3 GAST CHGA
48 ampulla of vater benign neoplasm 10.3 SST CHGA
49 gastric antral vascular ectasia 10.3 SST GAST
50 carotid body cancer 10.3 SST CHGA

Graphical network of the top 20 diseases related to Gastrinoma:



Diseases related to Gastrinoma

Symptoms & Phenotypes for Gastrinoma

MGI Mouse Phenotypes related to Gastrinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.1 CASR CCKBR GRP INS NMB POMC
2 endocrine/exocrine gland MP:0005379 9.81 CASR CCKBR CHGA GAST INS MEN1
3 digestive/alimentary MP:0005381 9.8 CASR CCKBR GAST INS MEN1 SST
4 homeostasis/metabolism MP:0005376 9.8 CASR CCKBR CHGA GAST GRP INS
5 nervous system MP:0003631 9.4 CASR CCKBR CHGA GRP INS MEN1

Drugs & Therapeutics for Gastrinoma

Drugs for Gastrinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 94)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
2
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
3 Gastrointestinal Agents Phase 4
4 Anti-Ulcer Agents Phase 4
5 Proton Pump Inhibitors Phase 4
6 Antacids Phase 4
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
8
Esomeprazole Approved, Investigational Phase 3 161973-10-0, 161796-78-7, 119141-88-7 4594 9568614
9
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
10
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2 149436
11
leucovorin Approved Phase 2, Phase 3 58-05-9 6006
12
Oxaliplatin Approved, Investigational Phase 2, Phase 3 61825-94-3 5310940 9887054 43805 6857599
13
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
14
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
15 Pancreatic Polypeptide Investigational Phase 2, Phase 3 59763-91-6
16 Cola Phase 3
17 Anesthetics Phase 3
18 Narcotics Phase 3
19 Analgesics, Opioid Phase 3
20 Analgesics Phase 3
21 Anesthetics, Intravenous Phase 3
22 Anesthetics, General Phase 3
23 Vitamin B9 Phase 2, Phase 3
24 Nutrients Phase 2, Phase 3
25 Micronutrients Phase 2, Phase 3
26 Trace Elements Phase 2, Phase 3
27 Protective Agents Phase 2, Phase 3
28 Vitamin B Complex Phase 2, Phase 3
29 Vitamins Phase 2, Phase 3
30 Folate Phase 2, Phase 3
31 Immunosuppressive Agents Phase 2, Phase 3
32 Antidotes Phase 2, Phase 3
33 Immunologic Factors Phase 2, Phase 3
34 Angiogenesis Inhibitors Phase 2, Phase 3
35 Antineoplastic Agents, Immunological Phase 2, Phase 3
36
Pancrelipase Approved, Investigational Phase 2 53608-75-6
37
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
38
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
39
Bortezomib Approved, Investigational Phase 2 179324-69-7 93860 387447
40
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
41
Streptozocin Approved, Investigational Phase 2 18883-66-4 29327
42
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
43
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
44
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
45
Pantoprazole Approved Phase 2 102625-70-7 4679
46
Omeprazole Approved, Investigational, Vet_approved Phase 2 73590-58-6 4594
47
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
48
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
49
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
50
Everolimus Approved Phase 2 159351-69-6 6442177 70789204

Interventional clinical trials:

(show all 45)
# Name Status NCT ID Phase Drugs
1 Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors Completed NCT00204373 Phase 4 Lansoprazole (Prevacid)
2 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 A Phase III, Multicenter, Open-Label Study To Evaluate the Control of Gastric Acid Secretion With Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome For 12 Months Completed NCT00079833 Phase 3 Esomeprazole magnesium (Nexium)
4 An Open-label, Parallel-group, Multi-centre, Phase I/III Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Repeated Once-daily Oral Administration of D961H 10 mg and D961H 20 mg in Japanese Paediatric Patients 1 to 14 Years Old With Gastrointestinal Acid Related Diseases Completed NCT02153398 Phase 3 D961H sachet 10 mg;D961H capsule 10mg;D961H capsule 20 mg
5 A Pilot Study of FOLFOX in Combination With Bevacizumab in Patients With Advanced Neuroendocrine Tumors Terminated NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
6 Study of First-Line Therapy Comprising Leucovorin Calcium, Fluorouracil, and Irinotecan (FOLFIRI) in Patients With Progressive Locally Advanced or Metastatic Duodenal-Pancreatic Endocrine Tumors Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
7 Phase II Trial Of Thalidomide In Patients With Low Grade Neuroendocrine Tumors (Carcinoid and Islet Cell Cancers) Completed NCT00027638 Phase 2 thalidomide
8 Phase II Study of PS-341 in Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
9 A Phase II Clinical and Biologic Study of AMG 706 and Octreotide in Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
10 A Randomised Phase II Study Comparing Capecitabine Plus Streptozocin With or Without Cisplatin Chemotherapy as Treatment for Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
11 A Phase II Trial of ZD1839 (Iressa®) in Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
12 Phase II Study of Single Agent Regorafenib in Patients With Advanced/Metastatic Neuroendocrine Tumors Completed NCT02259725 Phase 2 regorafenib
13 A Phase II Trial of Bay 43-9006 in Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
14 The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid Completed NCT00001191 Phase 2 Pantoprazole;Omeprazole
15 Evaluation of Treatment With Interferon, Octreotide, or Their Combination in Patients With Zollinger-Ellison Syndrome and Progressive Metastatic Non-B Islet Cell Neoplasm Completed NCT00001228 Phase 2 Interferon
16 A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
17 Evaluation of Chemotherapy With Streptozotocin Combined With 5-Fluorouracil and Adriamycin in Patients With Zollinger-Ellison Syndrome and Metastatic Non-Beta-Islet Cell Neoplasm Completed NCT00001165 Phase 2 combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
18 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
19 A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01824875 Phase 2 temozolomide;capecitabine
20 A Phase 2 Study of Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525082 Phase 2 Capecitabine;Temozolomide
21 Randomized Phase II Study of Everolimus Alone Versus Everolimus Plus Bevacizumab in Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01229943 Phase 2 Everolimus;Octreotide Acetate
22 Clinical Trial of Sir-Spheres® in Patients With Symptomatic or Progressive Hepatic Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
23 Phase II Study of Depsipeptide in Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
24 A Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Adjuvant Everolimus Following the Resection of Metastatic Pancreatic Neuroendocrine Tumors to the Liver Terminated NCT02031536 Phase 2 everolimus
25 Phase II Evaluation of Real-Time, Pharmacokinetically Guided Everolimus in Patients With Hormone Receptor Positive Breast Cancer, Pancreatic Neuroendocrine Tumors (PNET), and Renal Cell Carcinoma Terminated NCT02273752 Phase 2 Everolimus
26 A Pilot Trial of YF476, a Gastrin Antagonist, in Patients With Type II Gastric Carcinoids Associated With Zollinger-Ellison Syndrome Terminated NCT02454075 Phase 2 YF476
27 Phase II Study of Vatalanib and Octreotide in Patients With Progressive Low-Grade Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
28 Phase II Study of Dovitinib (TKI-258) in Progressive, Well-Differentiated Pancreatic Neuroendocrine Tumors With and Without Prior VEGF-Inhibitor Therapy Withdrawn NCT02108782 Phase 2 dovitinib lactate
29 A Phase I, Pharmacokinetic, and Biologic Correlative Study of R115777 (NSC 702818) and Herceptin in Patients With Advanced Cancer Completed NCT00005842 Phase 1 tipifarnib
30 A Phase I Study of Intraperitoneal Oxaliplatin Alone and in Combination With Intraperitoneal Floxuridine and Leucovorin in Patients With Advanced Metastatic Cancer Confined to the Peritoneal Cavity Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
31 A Phase I, Open-Label, Maximum Tolerated Single-Cycle and Four-Cycle Dose-Finding Study to Evaluation the Safety and Tolerability of 90Y-SMT 487 Administered by Intravenous Infusion to Subjects With Refractory Somatostatin-Receptor Positive Tumors Completed NCT00006368 Phase 1
32 A Phase I, Open Label, Maximum Tolerated Dose-Finding Study to Evaluate the Safety and Tolerability of 90Y-DOTA-tyr3-Octreotide Administered by Intravenous Infusion to Children With Refractory Somatostatin-Receptor Positive Tumors Completed NCT00049023 Phase 1
33 A Phase I Trial of the mTOR Inhibitor RAD001 in Combination With VEGF Receptor Tyrosine Kinase Inhibitor PTK787/ZK 222584 in Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
34 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
35 Phase I Study of Anti-IGF-1R Monoclonal Antibody, IMC-A12, and mTOR Inhibitor, Everolimus, in Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
36 Phase I Feasibility Trial To Study The Safety Of Sealing Resected Pancreatic Surfaces After Partial Distal Pancreatectomy Using Laser Tissue Welding Recruiting NCT03147768 Phase 1
37 A Phase I Study of [111In-DTPA-D-Phe]-Octreotide in Patients With Refractory Malignancies Expressing Somatostatin Receptors Terminated NCT00002947 Phase 1
38 A Phase 1 Study of Veliparib (ABT-888) in Combination With Capecitabine and Temozolomide in Advanced Well-Differentiated Neuroendocrine Tumors Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
39 Clinical and Psychometric Validation of a Disease-Specific Questionnaire Module in Assessing the Quality of Life of Patients With G.I.-Related Neuroendocrine Tumours Unknown status NCT00454376
40 Evaluation of the Gastrinoma in Patients With Zollinger-Ellison Syndrome Completed NCT00001254
41 Medical Therapy of Zollinger-Ellison Syndrome Completed NCT00001241
42 Diagnostic Evaluation of Patients With Suspected Abnormalities of Gastric Secretion Completed NCT00001240
43 Nexium Capsules Clinical Experience Investigation Completed NCT01434485
44 Evaluation of the Safety and Sensitivity of 68Ga-DOTATOC PET/CT for Imaging NET Patients Recruiting NCT03583528
45 Treatment of Patients With Hepatic Neuroendocrine Metastases Using Drug-Eluting Bead Embolization Terminated NCT00730483 PVA microporous hydrospheres/doxorubicin hydrochloride

Search NIH Clinical Center for Gastrinoma

Cochrane evidence based reviews: gastrinoma

Genetic Tests for Gastrinoma

Anatomical Context for Gastrinoma

MalaCards organs/tissues related to Gastrinoma:

40
Pancreas, Lymph Node, Liver, Pituitary, Pancreatic Islet, Endothelial, Bone

Publications for Gastrinoma

Articles related to Gastrinoma:

(show top 50) (show all 1288)
# Title Authors PMID Year
1
[Zollinger-Ellison syndrome: a case report.]. 61 54
20423792 2010
2
Review article: Strategies to determine whether hypergastrinaemia is due to Zollinger-Ellison syndrome rather than a more common benign cause. 54 61
19226290 2009
3
False-positive secretin stimulation test for gastrinoma associated with the use of proton pump inhibitor therapy. 54 61
19245850 2009
4
The glucagon provocative test for the diagnosis and treatment of Zollinger-Ellison syndrome. 54 61
17929104 2008
5
Regression of a large malignant gastrinoma on treatment with Sandostatin LAR: a case report. 61 54
18376130 2008
6
Novel association of duodenal gastrinoma and atrophic gastritis: case report and literature review. 54 61
18194935 2007
7
Chromogranin A in patients with acid hypersecretion and/or hypergastrinaemia. 54 61
17767471 2007
8
Biochemistry of neuroendocrine tumours. 54 61
17382264 2007
9
Gastrinoma--morphological aspects. 54 61
17985091 2007
10
Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. 61 54
17108778 2006
11
Increased islet beta cell replication adjacent to intrapancreatic gastrinomas in humans. 54 61
17016695 2006
12
Role of selective arterial secretin injection test in treatment of gastrinoma. 61 54
17153463 2006
13
Plasma gastrin measurement cannot be used to diagnose a gastrinoma in patients on either proton pump inhibitors or histamine type-2 receptor antagonists. 61 54
16536918 2006
14
Primary peripancreatic lymph node gastrinoma in a woman with MEN1. 54 61
17013727 2006
15
Fast cancer uptake of 99mTc-labelled bombesin (99mTc BN1). 61 54
16277024 2005
16
Multiple endocrine neoplasia type 1 gene mutations in sporadic gastrinomas in Japan. 61 54
15944766 2005
17
Precursor lesions in patients with multiple endocrine neoplasia type 1-associated duodenal gastrinomas. 61 54
15887103 2005
18
A follow-up study of patients with Zollinger-Ellison syndrome in the period 1966-2002: effects of surgical and medical treatments on long-term survival. 61 54
15815204 2005
19
Gastrin-17 specific antibodies are too specific for gastrinoma diagnosis but stain G-cells. 54 61
16036513 2005
20
Regression of type II gastric carcinoids in multiple endocrine neoplasia type 1 patients with Zollinger-Ellison syndrome after surgical excision of all gastrinomas. 54 61
15383867 2004
21
[The diagnosis and treatment of insulinoma and gastrinoma]. 54 61
15045936 2004
22
In situ analysis of human menin in normal and neoplastic pancreatic tissues: evidence for differential expression in exocrine and endocrine cells. 61 54
12915685 2003
23
Biochemical diagnosis of gastroenteropancreatic endocrine tumors. 54 61
12719697 2003
24
Octreotide in control of multiple liver metastases from gastrinoma. 54 61
14564638 2003
25
Intravenous calcium injection test is a novel complementary procedure in differential diagnosis for gastrinoma. 54 61
12205549 2002
26
Surgical experience with functioning pancreatic neuroendocrine tumors. 54 61
12206598 2002
27
Dominant negative action of an abnormal secretin receptor arising from mRNA missplicing in a gastrinoma. 61 54
11832464 2002
28
Use of secretin in the treatment of childhood autism. 61 54
11782669 2002
29
Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. 54 61
11701693 2001
30
Human gastrinoma cells express calcium-sensing receptor. 61 54
11787938 2001
31
Extreme hypergastrinemia caused by atrophic gastritis and Helicobacter pylori infection--a case report. 54 61
11490838 2001
32
Immunohistochemical assessment of an asymptomatic glucagonoma in a patient with hypergastrinemia and marked antral angiodysplasia. 54 61
11277423 2001
33
Diagnostic value of plasma chromogranin A in neuroendocrine tumours. 61 54
11204811 2001
34
Role of (111)In-DTPA-pentetreotide scintigraphy in accurate diagnosis of neuroendocrine gastroenteropancreatic tumors. 61 54
11702259 2001
35
Alterations in the p16INK4a/CDKN2A tumor suppressor gene in gastrinomas. 54 61
11095446 2000
36
Curative resection of microgastrinomas based on the intraoperative secretin test. 61 54
11038217 2000
37
Expression of the calcium-sensing receptor in gastrinomas. 61 54
11095444 2000
38
[Laboratory diagnosis of gastrinoma. Nordic collaboration can improve the quality]. 61 54
11036358 2000
39
Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. 54 61
11007228 2000
40
Primary nodal gastrinomas. 61 54
10835515 2000
41
Localization of gastroenteropancreatic tumours by angiography. 61 54
10604123 1999
42
Somatostatin scan positive gastrinoma ocular metastasis. 54 61
10636690 1999
43
The gene for multiple endocrine neoplasia type 1: recent findings. 61 54
10423035 1999
44
Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas. 61 54
10193936 1999
45
[Usefulness and limits of intraoperative hormone measurements in surgery of endocrine duodeno-pancreatic tumors: experience of 72 cases]. 54 61
10210744 1999
46
Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias. 61 54
10548885 1999
47
Functional pancreatic islet cell tumors with liver metastasis: the role of cytoreductive surgery and transcatheter arterial chemoembolization: a report of five cases. 61 54
9884450 1998
48
Gastrinoma: advances in localization and treatment. 61 54
9735137 1998
49
Duodenal gastrinoma--clinical features and usefulness of selective arterial secretin injection test. 61 54
9773940 1998
50
Mutation of the MENIN gene in sporadic pancreatic endocrine tumors. 54 61
9766672 1998

Variations for Gastrinoma

Expression for Gastrinoma

Search GEO for disease gene expression data for Gastrinoma.

Pathways for Gastrinoma

Pathways related to Gastrinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.73 VIP SSTR5 SSTR2 SSTR1 SST SCTR
2
Show member pathways
13.02 VIP SSTR5 SSTR2 SSTR1 SST SCTR
3
Show member pathways
12.43 SSTR5 SSTR2 SSTR1 SST POMC
4
Show member pathways
12.23 SSTR2 SST SCTR SCT GAST CCKBR
5 12.07 VIP SSTR5 SSTR2 SSTR1 SST POMC
6 11.83 VIP SCTR SCT POMC
7 11.23 SSTR2 CCKBR CASR
8 10.78 POMC INS
9 10.16 GAST CCKBR
10 9.77 VIP SCT GRP GAST

GO Terms for Gastrinoma

Cellular components related to Gastrinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.8 SST SCT POMC INS GRP GAST
2 extracellular region GO:0005576 9.61 VIP SST SCT POMC NMB INS
3 secretory granule lumen GO:0034774 9.33 POMC INS GRP
4 neuron projection GO:0043005 9.1 VIP SSTR5 SSTR2 SSTR1 NMB CASR

Biological processes related to Gastrinoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.96 VIP NMB INS CCKBR CASR
2 signal transduction GO:0007165 9.93 VIP SSTR5 SSTR2 SSTR1 SCTR POMC
3 negative regulation of cell proliferation GO:0008285 9.85 SSTR5 SSTR2 SSTR1 SST MEN1
4 cell-cell signaling GO:0007267 9.84 SST POMC NMB INS
5 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.67 SSTR5 SSTR2 SSTR1
6 glucose homeostasis GO:0042593 9.67 SSTR5 POMC NMB INS
7 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.65 VIP CCKBR CASR
8 regulation of synaptic plasticity GO:0048167 9.61 SCTR SCT INS
9 cellular response to glucocorticoid stimulus GO:0071385 9.59 SSTR5 SSTR2
10 positive regulation of blood vessel diameter GO:0097755 9.58 VIP INS
11 positive regulation of cAMP-mediated signaling GO:0043950 9.58 SCTR SCT
12 diet induced thermogenesis GO:0002024 9.57 SCTR SCT
13 positive regulation of peptide hormone secretion GO:0090277 9.55 INS GRP
14 negative regulation of blood vessel diameter GO:0097756 9.52 INS CHGA
15 cellular water homeostasis GO:0009992 9.51 SCTR SCT
16 regulation of appetite GO:0032098 9.5 SCTR SCT POMC
17 G protein-coupled receptor signaling pathway GO:0007186 9.47 VIP SSTR5 SSTR2 SSTR1 SST SCTR
18 somatostatin signaling pathway GO:0038170 9.43 SSTR5 SSTR2 SSTR1
19 neuropeptide signaling pathway GO:0007218 9.43 SSTR5 SSTR2 SSTR1 POMC NMB GRP
20 positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathway GO:1900738 9.4 GRP CHGA

Molecular functions related to Gastrinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.8 SSTR5 SSTR2 SSTR1 SCTR CCKBR CASR
2 peptide binding GO:0042277 9.54 SSTR5 SSTR2 SSTR1
3 neuropeptide hormone activity GO:0005184 9.43 VIP NMB GRP
4 neuropeptide binding GO:0042923 9.33 SSTR5 SSTR2 SSTR1
5 hormone activity GO:0005179 9.17 VIP SST SCT POMC NMB INS
6 somatostatin receptor activity GO:0004994 9.13 SSTR5 SSTR2 SSTR1

Sources for Gastrinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....